止血診断検査:医療機器パイプライン分析2017

◆英語タイトル:Haemostasis Diagnostic Tests - Medical Devices Pipeline Assessment, 2017
◆商品コード:GDME0446EPD
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年9月12日
◆ページ数:259
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD8,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD12,000 ⇒換算¥1,332,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Haemostasis Diagnostic Tests – Medical Devices Pipeline Assessment, 2017
Summary

GlobalData’s Medical Devices sector report, “Haemostasis Diagnostic Tests – Medical Devices Pipeline Assessment, 2017″ provides an overview of Haemostasis Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Haemostasis Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Haemostasis Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Haemostasis Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Haemostasis Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 12
2 Introduction 13
2.1 Haemostasis Diagnostic Tests Overview 13
3 Products under Development 14
3.1 Haemostasis Diagnostic Tests – Pipeline Products by Stage of Development 14
3.2 Haemostasis Diagnostic Tests – Pipeline Products by Segment 15
3.3 Haemostasis Diagnostic Tests – Pipeline Products by Territory 16
3.4 Haemostasis Diagnostic Tests – Pipeline Products by Regulatory Path 17
3.5 Haemostasis Diagnostic Tests – Pipeline Products by Estimated Approval Date 18
4 Haemostasis Diagnostic Tests – Pipeline Products under Development by Companies 19
4.1 Haemostasis Diagnostic Tests Companies – Pipeline Products by Stage of Development 19
4.2 Haemostasis Diagnostic Tests – Pipeline Products by Stage of Development 21
5 Haemostasis Diagnostic Tests Companies and Product Overview 26
5.1 Alere Inc Company Overview 26
5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 26
5.2 Analyticon Biotechnologies AG Company Overview 27
5.2.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 27
5.3 Bio-AMD Inc Company Overview 33
5.3.1 Bio-AMD Inc Pipeline Products & Ongoing Clinical Trials Overview 33
5.4 BioMedica USA LLC Company Overview 34
5.4.1 BioMedica USA LLC Pipeline Products & Ongoing Clinical Trials Overview 34
5.5 Braun Biosystems, Inc. Company Overview 35
5.5.1 Braun Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
5.6 Diagnostica Stago Inc Company Overview 36
5.6.1 Diagnostica Stago Inc Pipeline Products & Ongoing Clinical Trials Overview 36
5.7 ELITechGroup Inc Company Overview 42
5.7.1 ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 42
5.8 Emosis SAS Company Overview 43
5.8.1 Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview 43
5.9 Grifols Inc Company Overview 44
5.9.1 Grifols Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.10 Grifols SA Company Overview 46
5.10.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 46
5.11 Hansjorg Wyss Institute for Biologically Inspired Engineering Company Overview 60
5.11.1 Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview 60
5.12 Helena Laboratories Corp. Company Overview 61
5.12.1 Helena Laboratories Corp. Pipeline Products & Ongoing Clinical Trials Overview 61
5.13 HemoSonics, LLC Company Overview 67
5.13.1 HemoSonics, LLC Pipeline Products & Ongoing Clinical Trials Overview 67
5.14 Hologic Inc Company Overview 73
5.14.1 Hologic Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.15 Instrumentation Laboratory Company Company Overview 74
5.15.1 Instrumentation Laboratory Company Pipeline Products & Ongoing Clinical Trials Overview 74
5.16 Massachusetts General Hospital Company Overview 89
5.16.1 Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 89
5.17 Nexus Medical, LLC Company Overview 90
5.17.1 Nexus Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 90
5.18 Novametics, Inc. Company Overview 91
5.18.1 Novametics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 91
5.19 Pakwa Technologies Company Overview 92
5.19.1 Pakwa Technologies Pipeline Products & Ongoing Clinical Trials Overview 92
5.20 PortaScience Inc Company Overview 93
5.20.1 PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview 93
5.21 Radiometer Medical ApS Company Overview 94
5.21.1 Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview 94
5.22 Rappaport Family Institute for Research in the Medical Science Company Overview 96
5.22.1 Rappaport Family Institute for Research in the Medical Science Pipeline Products & Ongoing Clinical Trials Overview 96
5.23 rHealth Company Overview 97
5.23.1 rHealth Pipeline Products & Ongoing Clinical Trials Overview 97
5.24 Roche Diagnostics International Ltd Company Overview 98
5.24.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 98
5.25 SATT Conectus Alsace SAS Company Overview 100
5.25.1 SATT Conectus Alsace SAS Pipeline Products & Ongoing Clinical Trials Overview 100
5.26 Sekisui Medical Co Ltd Company Overview 101
5.26.1 Sekisui Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 101
5.27 Siemens Healthcare GmbH Company Overview 102
5.27.1 Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview 102
5.28 SonoMedix, Inc. Company Overview 125
5.28.1 SonoMedix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 125
5.29 SQI Diagnostics Inc Company Overview 126
5.29.1 SQI Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 126
5.30 Stichting Lygature Company Overview 127
5.30.1 Stichting Lygature Pipeline Products & Ongoing Clinical Trials Overview 127
5.31 Sysmex Corp Company Overview 129
5.31.1 Sysmex Corp Pipeline Products & Ongoing Clinical Trials Overview 129
5.32 Tarabios Company Overview 133
5.32.1 Tarabios Pipeline Products & Ongoing Clinical Trials Overview 133
5.33 Transfusion & Transplantation Technologies (Inactive) Company Overview 134
5.33.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 134
5.34 Universal Biosensors Inc Company Overview 135
5.34.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 135
5.35 University of Colorado Company Overview 136
5.35.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 136
5.36 University of Michigan Company Overview 137
5.36.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 137
5.37 University of Texas Health Science Center at Houston Company Overview 138
5.37.1 University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview 138
5.38 University of Vermont Company Overview 139
5.38.1 University of Vermont Pipeline Products & Ongoing Clinical Trials Overview 139
6 Haemostasis Diagnostic Tests – Recent Developments 140
6.1 Aug 24, 2017: SQI Diagnostics Reports Third Quarter 2017 Results 140
6.2 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 141
6.3 Aug 21, 2017: HemaCare Reports Strong First Half 2017 Results 144
6.4 Aug 15, 2017: T2 Biosystems and Aridis Pharmaceuticals Join Antimicrobials Working Group 144
6.5 Aug 07, 2017: Rick Legleiter Appointed Chief Executive Officer, Chairman Succession and Board Renewal Process 145
6.6 Aug 03, 2017: Siemens extends appointment of CEO Joe Kaeser 146
6.7 Aug 03, 2017: Siemens: Earnings Release Q3 FY 2017 146
6.8 Aug 03, 2017: Alere Reports Second Quarter 2017 Financial Results 148
6.9 Aug 03, 2017: T2 Biosystems Reports Second Quarter 2017 Financial Results; Provides Company Update 149
6.10 Aug 02, 2017: Hologic Announces Financial Results for Third Quarter of Fiscal 2017 150
6.11 Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 152
6.12 Jul 27, 2017: Abcam: Pre-Close Period Update 158
6.13 Jul 26, 2017: Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020 159
6.14 Jul 26, 2017: Thermo Fisher Scientific Reports Second Quarter 2017 Results 161
6.15 Jul 24, 2017: HemaCare Signs Long Term Lease for Facility Relocation and Expansion 163
6.16 Jul 20, 2017: Trinity Biotech Announces Results for Q2, 2017 163
6.17 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board 165
6.18 Jul 13, 2017: Dr. Jaymie Sawyer, Vice President of R&D, Transitions to Lead Scientific Advisory Committee 165
6.19 Jun 19, 2017: IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2017 165
6.20 Jun 14, 2017: Abbott Broadens Product Offering in Coagulation With Expanded Launch of the Sekisui CP3000 Fully Automated Coagulation System 166
6.21 Jun 14, 2017: Alere Reports First Quarter 2017 Financial Results 167
6.22 Jun 12, 2017: Siemens Healthineers Showcases its Atellica Diagnostics Portfolio and POC Informatics Solutions at EuroMedLab 168
6.23 Jun 05, 2017: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2016 Financial Results 169
6.24 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 169
6.25 May 23, 2017: Dan Buchner joins StarFish Medical business advisory board 172
6.26 May 22, 2017: Alere Provides Preliminary Unaudited Financial Results 173
6.27 May 18, 2017: Abcam Makes Final Performance-Based AxioMx Milestone Payment 174
6.28 May 16, 2017: Charles J. Dockendorff Elected to Hologic Board of Directors 174
6.29 May 10, 2017: Hologic Announces Financial Results for Second Quarter of Fiscal 2017 175
6.30 May 10, 2017: SQI Diagnostics Reports Second Quarter 2017 Results 176
6.31 May 08, 2017: Commencement of Xprecia Stride Coagulation Analyser sales activities in the US market 177
6.32 May 04, 2017: Siemens: Earnings Release and Financial Results Q2 FY 2017: Another strong quarter – profitable growth continuing 178
6.33 May 03, 2017: Bioscience Division sales increase 15% to drive Grifols’ revenue growth by 11% to Euros 1,062 million 180
6.34 May 02, 2017: T2 Biosystems Reports First Quarter 2017 Results and Corporate Update 184
6.35 May 01, 2017: T2 Biosystems Names Darlene Deptula-Hicks as Chief Financial Officer 186
6.36 Apr 27, 2017: Trinity Biotech Announces Results for Q1, 2017 186
6.37 Apr 27, 2017: Universal Biosensors reports strong growth in revenue and profit in Q1 2017 187
6.38 Apr 26, 2017: Thermo Fisher Scientific Reports First Quarter 2017 Results 188
6.39 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 190
6.40 Apr 03, 2017: Supervisory Board of Siemens Healthineers ensures management continuity 191
6.41 Apr 03, 2017: Sysmex Establishes New Company, Sysmex Harmony, to Promote the Employment of People with Disabilities 192
6.42 Mar 20, 2017: IBEX reports results for the second quarter and the six months ended January 31, 2017 192
6.43 Mar 17, 2017: Eva Schulz-Kamm appointed global head of Government Affairs at Siemens 193
6.44 Mar 14, 2017: Trinity Biotech announces Quarter 4 and Fiscal Year 2016 Financial Results 193
6.45 Mar 13, 2017: HemaCare Reports Strong, Profitable 2016 Results 195
6.46 Mar 09, 2017: Alere Provides Update on Arriva Medical 196
6.47 Mar 06, 2017: Abcam: Interim Results delivering double digit sales growth 196
6.48 Mar 01, 2017: Thermo Fisher Scientific Elects New Director to Board 197
6.49 Feb 28, 2017: Grifols’ revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 197
6.50 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 207
6.51 Feb 21, 2017: SQI Diagnostics Reports First Quarter 2017 Results 209
6.52 Feb 13, 2017: T2 Biosystems Reports Fourth Quarter and Full-Year 2016 Results 211
6.53 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 212
6.54 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 213
6.55 Feb 01, 2017: Jim Hagemann Snabe proposed as new Chairman of Siemens’ Supervisory Board 213
6.56 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 214
6.57 Feb 01, 2017: Hologic Announces Financial Results for First Quarter of Fiscal 2017 216
6.58 Jan 31, 2017: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2016 Results 218
6.59 Jan 31, 2017: Siemens: First Quarter Results FY 2017 220
6.60 Jan 23, 2017: ISO 17025 Accreditation for Microbiology Manufacturing Site Offers Increased Confidence to Microbiology Testing Laboratories 221
6.61 Jan 18, 2017: SQI Diagnostics Announces Change to its Board of Directors 221
6.62 Jan 09, 2017: T2 Biosystems Reports Preliminary Fourth Quarter Results and Operational Progress 221
6.63 Jan 04, 2017: Hologic Appoints President of EMEA and Canada, Completing International Leadership Team 222
6.64 Jan 04, 2017: Alere Laboratory Receives ABFT Accreditation 222
6.65 Jan 04, 2017: Alere Provides Update on Arriva Medical 223
6.66 Dec 28, 2016: Alere Provides Update on Arriva Medical 223
6.67 Dec 16, 2016: IBEX Reports First Quarter Fiscal 2017 Results 224
6.68 Dec 16, 2016: Amy Wendell Elected to Hologic Board of Directors 225
6.69 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe 225
6.70 Dec 08, 2016: Khang & Khang Announces Securities Class Action Lawsuit against Alere and Reminds Investors with Losses to Contact the Firm 226
6.71 Dec 07, 2016: Abbott Seeks To Terminate Alere Acquisition 226
6.72 Nov 22, 2016: Siemens Healthineers Launches Atellica COAG 360 System High-Volume Specialty Hemostasis Analyzer 227
6.73 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 228
6.74 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 230
6.75 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 231
6.76 Nov 10, 2016: Siemens intends to further strengthen its healthcare business 232
6.77 Nov 08, 2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols’ revenues to EUR 2,952 million 232
6.78 Nov 04, 2016: Alere Reports Third Quarter 2016 Financial Results 237
6.79 Nov 04, 2016: IBEX Reports Results for The Year Ended July 31, 2016 237
6.80 Nov 02, 2016: Lak Ananth to head new next47 startup unit 238
6.81 Nov 02, 2016: Hologic Announces Financial Results for Fourth Quarter of Fiscal 2016 239
6.82 Nov 01, 2016: T2 Biosystems Reports Third Quarter Results 240
6.83 Oct 27, 2016: Thermo Fisher Scientific Reports Third Quarter 2016 Results 242
6.84 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 243
6.85 Oct 25, 2016: Trinity Biotech announces Quarter 3 Financial Results 245
6.86 Oct 24, 2016: Abcam commits to the lease of a new facility on the Cambridge Biomedical Campus 247
6.87 Oct 11, 2016: Instrumentation Laboratory Launches HemosIL AcuStar VWF:CB Assay In Europe And Other International Markets 248
6.88 Oct 04, 2016: Siemens Receives FDA Clearance of the Xprecia Stride Coagulation Analyzer 248
6.89 Sep 26, 2016: Instrumentation Laboratory Launches HemoHub Intelligent Data Manager Worldwide 249
6.90 Sep 23, 2016: Siegfried Russwurm to resign by mutual agreement from the Siemens Management Board 250
6.91 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 250
6.92 Sep 12, 2016: ABCAM: Strong revenue performance enabling investment for future growth 251
7 Appendix 255
7.1 Methodology 256
7.2 About GlobalData 259
7.3 Contact Us 259
7.4 Disclaimer 259

1.1 List of Tables
Table 1: Haemostasis Diagnostic Tests - Pipeline Products by Stage of Development 14
Table 2: Haemostasis Diagnostic Tests - Pipeline Products by Segment 15
Table 3: Haemostasis Diagnostic Tests - Pipeline Products by Territory 16
Table 4: Haemostasis Diagnostic Tests - Pipeline Products by Regulatory Path 17
Table 5: Haemostasis Diagnostic Tests - Pipeline Products by Estimated Approval Date 18
Table 6: Haemostasis Diagnostic Tests Companies - Pipeline Products by Stage of Development 19
Table 7: Haemostasis Diagnostic Tests - Pipeline Products by Stage of Development 21
Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 9: Afinion PT Test - Capillary Blood - Product Status 26
Table 10: Afinion PT Test - Capillary Blood - Product Description 26
Table 11: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 27
Table 12: Coagulyzer 1 - Product Status 27
Table 13: Coagulyzer 1 - Product Description 28
Table 14: Coagulyzer 100 - Product Status 28
Table 15: Coagulyzer 100 - Product Description 29
Table 16: Coagulyzer 2 - Product Status 29
Table 17: Coagulyzer 2 - Product Description 30
Table 18: Coagulyzer 4 - Product Status 30
Table 19: Coagulyzer 4 - Product Description 30
Table 20: Fibrinogen Lyophilisat Coagulation Kit - Product Status 31
Table 21: Fibrinogen Lyophilisat Coagulation Kit - Product Description 31
Table 22: Prothrombin Time Coagulation Reagent - Product Status 31
Table 23: Prothrombin Time Coagulation Reagent - Product Description 32
Table 24: Bio-AMD Inc Pipeline Products & Ongoing Clinical Trials Overview 33
Table 25: COAG Test Strip - Product Status 33
Table 26: COAG Test Strip - Product Description 33
Table 27: BioMedica USA LLC Pipeline Products & Ongoing Clinical Trials Overview 34
Table 28: Portable Diagnostic System - Hemostasis - Product Status 34
Table 29: Portable Diagnostic System - Hemostasis - Product Description 34
Table 30: Braun Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
Table 31: Bio6 - Product Status 35
Table 32: Bio6 - Product Description 35
Table 33: Diagnostica Stago Inc Pipeline Products & Ongoing Clinical Trials Overview 36
Table 34: Calibrated Automated Thrombogram - Thrombin Assay - Product Status 36
Table 35: Calibrated Automated Thrombogram - Thrombin Assay - Product Description 37
Table 36: STA Compact Max - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Status 37
Table 37: STA Compact Max - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Description 37
Table 38: STA-R Evolution Expert - Automated Ecarin Chromogenic Assay - Product Status 38
Table 39: STA-R Evolution Expert - Automated Ecarin Chromogenic Assay - Product Description 38
Table 40: STA-R Evolution Expert - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Status 38
Table 41: STA-R Evolution Expert - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Description 39
Table 42: STA-R Evolution Plus - Automated Ecarin Chromogenic Assay - Product Status 39
Table 43: STA-R Evolution Plus - Automated Ecarin Chromogenic Assay - Product Description 39
Table 44: STA-R Evolution Plus - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Status 40
Table 45: STA-R Evolution Plus - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Description 40
Table 46: STA-R Max - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Status 40
Table 47: STA-R Max - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Description 41
Table 48: ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 42
Table 49: ELITe InGenius - Coagulation Factors Panel - Product Status 42
Table 50: ELITe InGenius - Coagulation Factors Panel - Product Description 42
Table 51: Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview 43
Table 52: Hypercoagulation Diagnostics Kit - Product Status 43
Table 53: Hypercoagulation Diagnostics Kit - Product Description 43
Table 54: Grifols Inc Pipeline Products & Ongoing Clinical Trials Overview 44
Table 55: DG-PT - Product Status 44
Table 56: DG-PT - Product Description 44
Table 57: Q Hemostasis Analyzer - Product Status 45
Table 58: Q Hemostasis Analyzer - Product Description 45
Table 59: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 46
Table 60: DG-APC - Product Status 47
Table 61: DG-APC - Product Description 47
Table 62: DG-Chrom Hep - Product Status 47
Table 63: DG-Chrom Hep - Product Description 48
Table 64: DG-Chrom PC - Product Status 48
Table 65: DG-Chrom PC - Product Description 48
Table 66: Hemostasis Reagent Kit - DG-APTT Synth G-Fib L Human - Product Status 49
Table 67: Hemostasis Reagent Kit - DG-APTT Synth G-Fib L Human - Product Description 49
Table 68: Hemostasis Reagent Kit - DG-FII - Product Status 49
Table 69: Hemostasis Reagent Kit - DG-FII - Product Description 49
Table 70: Hemostasis Reagent Kit - DG-FIX - Product Status 50
Table 71: Hemostasis Reagent Kit - DG-FIX - Product Description 50
Table 72: Hemostasis Reagent Kit - DG-FV - Product Status 50
Table 73: Hemostasis Reagent Kit - DG-FV - Product Description 51
Table 74: Hemostasis Reagent Kit - DG-FVII - Product Status 51
Table 75: Hemostasis Reagent Kit - DG-FVII - Product Description 51
Table 76: Hemostasis Reagent Kit - DG-FVIII - Product Status 52
Table 77: Hemostasis Reagent Kit - DG-FVIII - Product Description 52
Table 78: Hemostasis Reagent Kit - DG-FX - Product Status 52
Table 79: Hemostasis Reagent Kit - DG-FX - Product Description 52
Table 80: Hemostasis Reagent Kit - DG-FXI - Product Status 53
Table 81: Hemostasis Reagent Kit - DG-FXI - Product Description 53
Table 82: Hemostasis Reagent Kit - DG-FXII - Product Status 53
Table 83: Hemostasis Reagent Kit - DG-FXII - Product Description 54
Table 84: Hemostasis Reagent Kit - DG-Latex D Dimer - Product Status 54
Table 85: Hemostasis Reagent Kit - DG-Latex D Dimer - Product Description 54
Table 86: Hemostasis Reagent Kit - DG-Latex VWF: Gp1b - Product Status 55
Table 87: Hemostasis Reagent Kit - DG-Latex VWF: Gp1b - Product Description 55
Table 88: Hemostasis Reagent Kit - DG-PT RecombiLIQ - Product Status 55
Table 89: Hemostasis Reagent Kit - DG-PT RecombiLIQ - Product Description 56
Table 90: Hemostasis Reagent Kit - DG-TT L Human - Product Status 56
Table 91: Hemostasis Reagent Kit - DG-TT L Human - Product Description 56
Table 92: Thrombophilia Reagent Kit - DG-Chrom Anti Xa - Product Status 56
Table 93: Thrombophilia Reagent Kit - DG-Chrom Anti Xa - Product Description 57
Table 94: Thrombophilia Reagent Kit - DG-Chrom AT L - Product Status 57
Table 95: Thrombophilia Reagent Kit - DG-Chrom AT L - Product Description 57
Table 96: Thrombophilia Reagent Kit - DG-Clot PS - Product Status 58
Table 97: Thrombophilia Reagent Kit - DG-Clot PS - Product Description 58
Table 98: Thrombophilia Reagent Kit - DG-DRVVT - Product Status 58
Table 99: Thrombophilia Reagent Kit - DG-DRVVT - Product Description 58
Table 100: Thrombophilia Reagent Kit - DG-DRVVT Confirm - Product Status 59
Table 101: Thrombophilia Reagent Kit - DG-DRVVT Confirm - Product Description 59
Table 102: Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview 60
Table 103: Hemostasis Monitoring Microfluidic Device - Product Status 60
Table 104: Hemostasis Monitoring Microfluidic Device - Product Description 60
Table 105: Helena Laboratories Corp. Pipeline Products & Ongoing Clinical Trials Overview 61
Table 106: Actalyke Mini II - APTT Test - Product Status 61
Table 107: Actalyke Mini II - APTT Test - Product Description 61
Table 108: Actalyke Mini II - LMWH Test - Product Status 62
Table 109: Actalyke Mini II - LMWH Test - Product Description 62
Table 110: Actalyke Mini II - PT Test - Product Status 62
Table 111: Actalyke Mini II - PT Test - Product Description 62
Table 112: Actalyke XL - APTT Test - Product Status 63
Table 113: Actalyke XL - APTT Test - Product Description 63
Table 114: Actalyke XL - Heparin Test - Product Status 63
Table 115: Actalyke XL - Heparin Test - Product Description 63
Table 116: Actalyke XL - LMWH Test - Product Status 64
Table 117: Actalyke XL - LMWH Test - Product Description 64
Table 118: Actalyke XL - PT Test - Product Status 64
Table 119: Actalyke XL - PT Test - Product Description 64
Table 120: Cascade Abrazo Analyzer - Product Status 65
Table 121: Cascade Abrazo Analyzer - Product Description 65
Table 122: Cascade M - DRVVT Test - Product Status 65
Table 123: Cascade M - DRVVT Test - Product Description 66
Table 124: Cascade M-4 - DRVVT Test - Product Status 66
Table 125: Cascade M-4 - DRVVT Test - Product Description 66
Table 126: HemoSonics, LLC Pipeline Products & Ongoing Clinical Trials Overview 67
Table 127: HemoSonics Global Hemostasis Analyzer - Chronic Liver Disease - Product Status 67
Table 128: HemoSonics Global Hemostasis Analyzer - Chronic Liver Disease - Product Description 68
Table 129: HemoSonics Global Hemostasis Analyzer - Intensive Care - Product Status 68
Table 130: HemoSonics Global Hemostasis Analyzer - Intensive Care - Product Description 68
Table 131: HemoSonics Global Hemostasis Analyzer - Neurosurgery - Product Status 69
Table 132: HemoSonics Global Hemostasis Analyzer - Neurosurgery - Product Description 69
Table 133: HemoSonics Global Hemostasis Analyzer - Oral Contraception - Product Status 69
Table 134: HemoSonics Global Hemostasis Analyzer - Oral Contraception - Product Description 70
Table 135: HemoSonics Global Hemostasis Analyzer - Orthopedic Surgery - Product Status 70
Table 136: HemoSonics Global Hemostasis Analyzer - Orthopedic Surgery - Product Description 70
Table 137: HemoSonics Global Hemostasis Analyzer - Perinatal Care - Product Status 71
Table 138: HemoSonics Global Hemostasis Analyzer - Perinatal Care - Product Description 71
Table 139: HemoSonics Global Hemostasis Analyzer - Trauma - Product Status 71
Table 140: HemoSonics Global Hemostasis Analyzer - Trauma - Product Description 72
Table 141: HemoSonics Global Hemostasis Analyzer HS-GHA - Product Status 72
Table 142: HemoSonics Global Hemostasis Analyzer HS-GHA - Product Description 72
Table 143: Hologic Inc Pipeline Products & Ongoing Clinical Trials Overview 73
Table 144: Diagnostic Assay - Coagulation Disorders - Product Status 73
Table 145: Diagnostic Assay - Coagulation Disorders - Product Description 73
Table 146: Instrumentation Laboratory Company Pipeline Products & Ongoing Clinical Trials Overview 74
Table 147: ACL AcuStar - aß2GPI Domain I Assay - Product Status 75
Table 148: ACL AcuStar - aß2GPI Domain I Assay - Product Description 75
Table 149: ACL AcuStar - HIT IgG Test - Product Status 75
Table 150: ACL AcuStar - HIT IgG Test - Product Description 76
Table 151: ACL AcuStar - HIT Total ab Test - Product Status 76
Table 152: ACL AcuStar - HIT Total ab Test - Product Description 76
Table 153: ACL AcuStar - VWF: RCo Assay - Product Status 77
Table 154: ACL AcuStar - VWF: RCo Assay - Product Description 77
Table 155: ACL AcuStar - VWF:Ag Assay - Product Status 77
Table 156: ACL AcuStar - VWF:Ag Assay - Product Description 78
Table 157: ACL TOP 300 CTS system - Global Protein C Pathway Test - Product Status 78
Table 158: ACL TOP 300 CTS system - Global Protein C Pathway Test - Product Description 78
Table 159: ACL TOP 300 CTS System - HIT Assay - Product Status 78
Table 160: ACL TOP 300 CTS System - HIT Assay - Product Description 79
Table 161: ACL TOP 300 CTS System - VWF-Ristocetin Cofactor - Product Status 79
Table 162: ACL TOP 300 CTS System - VWF-Ristocetin Cofactor - Product Description 79
Table 163: ACL TOP 350 CTS System - VWF (Ristocetin Cofactor) Assay - Product Status 80
Table 164: ACL TOP 350 CTS System - VWF (Ristocetin Cofactor) Assay - Product Description 80
Table 165: ACL TOP 500 CTS System - Global Protein C Pathway Test - Product Status 80
Table 166: ACL TOP 500 CTS System - Global Protein C Pathway Test - Product Description 80
Table 167: ACL TOP 500 CTS System - HIT Test - Product Status 81
Table 168: ACL TOP 500 CTS System - HIT Test - Product Description 81
Table 169: ACL TOP 500 CTS System - VWF - Ristocetin Cofactor - Product Status 81
Table 170: ACL TOP 500 CTS System - VWF - Ristocetin Cofactor - Product Description 82
Table 171: ACL TOP 550 CTS System - VWF (Ristocetin Cofactor) Assay - Product Status 82
Table 172: ACL TOP 550 CTS System - VWF (Ristocetin Cofactor) Assay - Product Description 82
Table 173: ACL TOP 700 - HIT Test - Product Status 83
Table 174: ACL TOP 700 - HIT Test - Product Description 83
Table 175: ACL TOP 700 CTS System - VWF - Ristocetin Cofactor - Product Status 83
Table 176: ACL TOP 700 CTS System - VWF - Ristocetin Cofactor - Product Description 83
Table 177: ACL TOP 700 System - Global Protein C Pathway Test - Product Status 84
Table 178: ACL TOP 700 System - Global Protein C Pathway Test - Product Description 84
Table 179: ACL TOP 750 CTS System - VWF (Ristocetin Cofactor) Assay - Product Status 84
Table 180: ACL TOP 750 CTS System - VWF (Ristocetin Cofactor) Assay - Product Description 84
Table 181: Dabigatran Direct Thrombin Inhibitor Assay - Product Status 85
Table 182: Dabigatran Direct Thrombin Inhibitor Assay - Product Description 85
Table 183: HemoSIL ACL AcuStar - VWF:CB Assay - Product Status 85
Table 184: HemoSIL ACL AcuStar - VWF:CB Assay - Product Description 86
Table 185: HemosIL AcuStar HIT-IgG (PF4-H) Assay - Product Status 86
Table 186: HemosIL AcuStar HIT-IgG (PF4-H) Assay - Product Description 86
Table 187: HemosIL Apixaban Testing Assay - Product Status 87
Table 188: HemosIL Apixaban Testing Assay - Product Description 87
Table 189: HemosIL FDP Assay - Product Status 87
Table 190: HemosIL FDP Assay - Product Description 88
Table 191: Rivaroxaban Liquid Anti-Xa Assay - Product Status 88
Table 192: Rivaroxaban Liquid Anti-Xa Assay - Product Description 88
Table 193: Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 89
Table 194: High Throughput Screening Assay - Fibrin-Binding Probes - Product Status 89
Table 195: High Throughput Screening Assay - Fibrin-Binding Probes - Product Description 89
Table 196: Nexus Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 90
Table 197: ProTime InRhythm - Product Status 90
Table 198: ProTime InRhythm - Product Description 90
Table 199: Novametics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 91
Table 200: Blood Coagulation Diagnostic Assay - Product Status 91
Table 201: Blood Coagulation Diagnostic Assay - Product Description 91
Table 202: Pakwa Technologies Pipeline Products & Ongoing Clinical Trials Overview 92
Table 203: Platelet ActiSense - Product Status 92
Table 204: Platelet ActiSense - Product Description 92
Table 205: PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview 93
Table 206: PortaPT - Product Status 93
Table 207: PortaPT - Product Description 93
Table 208: Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview 94
Table 209: AQT90 - APTT Test - Product Status 94
Table 210: AQT90 - APTT Test - Product Description 94
Table 211: AQT90 - PT-INR Test - Product Status 95
Table 212: AQT90 - PT-INR Test - Product Description 95
Table 213: Rappaport Family Institute for Research in the Medical Science Pipeline Products & Ongoing Clinical Trials Overview 96
Table 214: Diagnostic Kit - Hypercoagulation - Product Status 96
Table 215: Diagnostic Kit - Hypercoagulation - Product Description 96
Table 216: rHealth Pipeline Products & Ongoing Clinical Trials Overview 97
Table 217: rHEALTH Coagulation Assay - Product Status 97

1.2 List of Figures
Figure 1: Haemostasis Diagnostic Tests - Pipeline Products by Stage of Development 14
Figure 2: Haemostasis Diagnostic Tests - Pipeline Products by Segment 15
Figure 3: Haemostasis Diagnostic Tests - Pipeline Products by Territory 16
Figure 4: Haemostasis Diagnostic Tests - Pipeline Products by Regulatory Path 17
Figure 5: Haemostasis Diagnostic Tests - Pipeline Products by Estimated Approval Date 18

【掲載企業】

Alere Inc
Analyticon Biotechnologies AG
Bio-AMD Inc
BioMedica USA LLC
Braun Biosystems, Inc.
Diagnostica Stago Inc
ELITechGroup Inc
Emosis SAS
Grifols Inc
Grifols SA
Hansjorg Wyss Institute for Biologically Inspired Engineering
Helena Laboratories Corp.
HemoSonics, LLC
Hologic Inc
Instrumentation Laboratory Company
Massachusetts General Hospital
Nexus Medical, LLC
Novametics, Inc.
Pakwa Technologies
PortaScience Inc
Radiometer Medical ApS
Rappaport Family Institute for Research in the Medical Science
rHealth
Roche Diagnostics International Ltd
SATT Conectus Alsace SAS
Sekisui Medical Co Ltd
Siemens Healthcare GmbH
SonoMedix, Inc.
SQI Diagnostics Inc
Stichting Lygature
Sysmex Corp
Tarabios
Transfusion & Transplantation Technologies
Universal Biosensors Inc
University of Colorado
University of Michigan
University of Texas Health Science Center at Houston
University of Vermont

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 止血診断検査:医療機器パイプライン分析2017(Haemostasis Diagnostic Tests - Medical Devices Pipeline Assessment, 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆